Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
Abstract Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory autoimmune disease that mainly involves the optic nerves and spinal cord, causing blindness and paralysis. Although some immunosuppressants such as rituximab and azathioprine have proven to be effective in relapse preve...
Main Authors: | Bo Chen, Qian Wu, Gaotan Ke, Bitao Bu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-04-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-00860-y |
Similar Items
-
Treatment of Neuromyelitis Optica Spectrum Disorders
by: Koon-Ho Chan, et al.
Published: (2021-08-01) -
Neuromyelitis optica spectrum disorders: An update
by: Lekha Pandit
Published: (2015-01-01) -
Neuromyelitis optica spectrum disorders in pediatric patients
by: Yu. V. Tokareva, et al.
Published: (2018-04-01) -
Late Onset of Neuromyelitis Optica Spectrum Disorders
by: Yara Dadalti Fragoso, et al.
Published: (2019-07-01) -
Targeted therapy for neuromyelitis optica spectrum disorders
by: Yang⁃tai GUAN
Published: (2020-10-01)